title: Quality of life in thalassemia.
abstract: Morbidity and mortality related to thalassemia have been reduced significantly with modern medical treatment, and quality of life (QOL) should now be considered an important index of effective health care. An assessment of QOL differs from other forms of medical assessment in that it focuses on the individuals' own views of their well-being and assesses other aspects of life, giving a more holistic view of well-being. There is very little published work on evaluation of QOL in thalassemia. A suitable tool should be reproducible, sensitive to the major features of the condition that affect patients' lives, and applicable in the range of different cultural, age, and social settings. Such an instrument would be valuable in evaluating new forms of treatment and in comparing health outcomes between different clinics. Two instruments have been assessed, one derived from the WHOQOL-100 questionnaire, and one designed specifically for thalassemia, which assesses psychosocial and clinical burden, as they affect adult patients, parents, and children. Further studies are required to develop and assess such tools for use in thalassemia. Another approach is to seek patients' own views of their routine treatment and the extent to which medical treatment affects QOL. Results from patient questionnaires in the United Kingdom and Cyprus are consistent in finding problems with organization of transfusions, insufficient options with chelation therapy, and poor communication. Practical measures could be taken to address these issues.
authors.affiliation: Department of Haematology, St. Bartholomew's Hospital, London, UK. paul.telfer@bartsandthelondon.nhs.uk
authors.forename: P
authors.initials: P
authors.lastname: Telfer
authors.forename: G
authors.initials: G
authors.lastname: Constantinidou
authors.forename: P
authors.initials: P
authors.lastname: Andreou
authors.forename: S
authors.initials: S
authors.lastname: Christou
authors.forename: B
authors.initials: B
authors.lastname: Modell
authors.forename: M
authors.initials: M
authors.lastname: Angastiniotis
mesh_terms: D000293:Adolescent; D000328:Adult; D017028:Caregivers / Q000523:psychology; D002614:Chelating Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015913:Chelation Therapy / Q000523:psychology; D002648:Child; D002675:Child, Preschool; D003535:Cyprus; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D007279:Injections, Subcutaneous / Q000523:psychology; D008297:Male; D010290:Parents / Q000523:psychology; D010349:Patient Compliance; D011788:Quality of Life; D012959:Socioeconomic Factors; D011795:Surveys and Questionnaires; D013789:Thalassemia / Q000188:drug therapy / Q000523:psychology* / Q000628:therapy; D006113:United Kingdom
chemical_list: D002614:Chelating Agents; D003676:Deferoxamine